BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 24618912)

  • 21. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
    Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
    Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
    JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SERMs for the treatment and prevention of breast cancer.
    Swaby RF; Sharma CG; Jordan VC
    Rev Endocr Metab Disord; 2007 Sep; 8(3):229-39. PubMed ID: 17440819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
    Visvanathan K; Chlebowski RT; Hurley P; Col NF; Ropka M; Collyar D; Morrow M; Runowicz C; Pritchard KI; Hagerty K; Arun B; Garber J; Vogel VG; Wade JL; Brown P; Cuzick J; Kramer BS; Lippman SM;
    J Clin Oncol; 2009 Jul; 27(19):3235-58. PubMed ID: 19470930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast cancer risk reduction therapy: the low-hanging fruit.
    Bevers TB
    J Natl Compr Canc Netw; 2015 Apr; 13(4):376-8. PubMed ID: 25870373
    [No Abstract]   [Full Text] [Related]  

  • 26. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
    Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
    J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast cancer chemoprevention.
    Rosenbaum Smith SM; Osborne MP
    Am J Surg; 2000 Oct; 180(4):249-51. PubMed ID: 11113429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen.
    Prescrire Int; 2005 Jun; 14(77):108-10. PubMed ID: 15984106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormones 'R' us.
    Sledge GW
    Clin Breast Cancer; 2002 Jan; 2(4):251. PubMed ID: 11899355
    [No Abstract]   [Full Text] [Related]  

  • 32. Breast cancer prevention trials.
    Rhodes DJ; Hartmann LC; Perez EA
    Curr Oncol Rep; 2000 Nov; 2(6):558-65. PubMed ID: 11122893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.
    Dhingra K
    Cancer Invest; 2001; 19(6):649-59. PubMed ID: 11486708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aromatase inhibitors in breast cancer prevention.
    Olin JL; St Pierre M
    Ann Pharmacother; 2014 Dec; 48(12):1605-10. PubMed ID: 25159003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of hormone-related cancers: breast cancer.
    Dunn BK; Wickerham DL; Ford LG
    J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
    Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R; Alvarez M; Crew KD
    Breast J; 2015; 21(4):377-86. PubMed ID: 25879521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
    Sénéchal C; Reyal F; Callet N; This P; Noguès C; Stoppa-Lyonnet D; Fourme E
    Bull Cancer; 2016 Mar; 103(3):273-81. PubMed ID: 26852151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.
    Zujewski J
    Environ Mol Mutagen; 2002; 39(2-3):264-70. PubMed ID: 11921197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of breast cancer using SERMs and aromatase inhibitors.
    Strassmer-Weippl K; Goss PE
    J Mammary Gland Biol Neoplasia; 2003 Jan; 8(1):5-18. PubMed ID: 14587860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.